Clinical trial
A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost 0.005%.
NCT00638742 is registered in ClinicalTrials.gov with Pfizer's Upjohn has merged with Mylan to form Viatris Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost 0.005%.
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 31, 2008
- Completion date
- March 31, 2009
- Enrollment
- 47 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.